New insights into lipid management have emerged since 2016. Prof. Ray discusses with prof. Mach in which respects the guidelines should be changed.
This video was recorded during an expert meeting among cardiologists and internists, focussing on the topic of 'LDL-c & PCSK9 inhibition in high CV risk patients - Balancing Science, Guidelines and Daily Cardiology Practice'.
The objectives of the meeting were to:
- Review recent outcome data with PCSK9 inhibitors in the clinical management of patients who had a recent MI
- Discuss the importance of reaching LDL-c targets in patients post MI
- Provide a European expert perspective on the current challenges of reaching LDL-c targets and use of PCSK9 inhibitors in clinical cardiology
- Define key challenges, needs and goals for education to ensure the implications of new outcome trials like FOURIER and ODYSSEY-outcomes will be adopted in post MI patients
- Develop a consensus and clinical guidance on lowering LDL-c in post MI patients
Prof. Kausik Ray , cardiologist, Imperial College London, United Kingdom
Prof. François Mach , cardiologist, University of Geneva, Switzerland
This recording was independently developed under auspices of PACE-cme. The views expressed in this recording are those of the individual presenters and do not necessarily reflect the views of PACE-cme.
Funding for the Expert Meeting was provided by an unrestricted educational grant from Amgen. The sponsor did not attend and influence the video recording.The content is aimed for medical professionals. To view this item member registration is needed. Register for free to get unlimited access to our educational resources.The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.
- LDL-c Expert MeetingProgressive CAD despite low LDL-C, an elusive disease?
- LDL-c Expert MeetingAre very low LDL-c levels safe?
- LDL-c Expert MeetingLDL-c as target in cardiology: The road towards lower targets
- LDL-c Expert MeetingHow are the guidelines for progressive CAD guiding us in clinical practice?